PointState Capital’s Gilead Sciences GILD Stock Holding History

PointState Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-60,000	Closed	-$4.13M	–	145
2021 Q3	$4.19M	Buy	+60,000	New	+$4.22M	0.07%	108
2021 Q2	–	Sell	-185,000	Closed	-$12.4M	–	149
2021 Q1	$12M	Buy	185,000 +96,069	+108%	+$6.19M	0.24%	73
2020 Q4	$5.18M	Buy	88,931 +6,431	+8%	+$388K	0.1%	91
2020 Q3	$5.21M	Sell	82,500 -304,817	-79%	-$21.1M	0.14%	69
2020 Q2	$29.8M	Buy	387,317 +31,646	+9%	+$2.43M	0.9%	24
2020 Q1	$26.6M	Buy	355,671 +310,455	+687%	+$21.5M	1.32%	18
2019 Q4	$2.94M	Buy	+45,216	New	+$2.94M	0.05%	77
2018 Q2	–	Sell	-1,148,301	Closed	-$86.6M	–	179
2018 Q1	$86.6M	Buy	+1,148,301	New	+$91.3M	0.94%	36
2013 Q3	–	Sell	-1,163,100	Closed	-$59.6M	–	145
2013 Q2	$59.6M	Buy	+1,163,100	New	+$60.6M	1.03%	23

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PointState Capital's GILD Position: Q4 2021 in Review

PointState Capital sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 60,000 shares — an estimated $4.13M sold.

PointState Capital first reported a position in GILD in Q2 2013 and held it in 9 quarters. The position peaked at $86.6M in Q1 2018. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

PointState Capital reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
PointState Capital sold 60,000 Gilead Sciences shares in Q4 2021, an estimated $4.13M.
PointState Capital first reported a position in Gilead Sciences in Q2 2013 and held it in 9 quarters.
PointState Capital's Gilead Sciences position peaked at $86.6M in Q1 2018.
1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.